The tumor rejection rates were 20% in the age-matched control, 60% in mice previously treated with vehicle plus anti–CTLA-4, and 100% in mice previously treated with 7HP349 plus anti–CTLA-4 (Figure 11, B–E). Here, CTLA4 is linked to neoplasm.